In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines

Anti-Cancer Drugs

Volumn 17, Issue 4, 2006, Pages 445-453

  Qin, Baoli ^a   Tanaka, Risa ^a   Shibata, Yoshihiro ^a   Arita, Shuji ^a   Ariyama, Hiroshi ^a   Kusaba, Hitoshi ^a   Baba, Eishi ^a   Harada, Mine ^a   Nakano, Shuji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Drug interaction; Oxaliplatin; Schedule dependence

Indexed keywords

FLUOROURACIL; OXALIPLATIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL ASSAY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STOMACH ADENOCARCINOMA; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FLUOROURACIL; HUMANS; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS;

EID: 33748183299     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000198912.98442.cd     Document Type: Article

References (41)

1. Tsai JY, Safran H. Status of treatment for advanced gastric carcinoma. Curr Oncol Rep 2003; 5:210-218.
2. Ho D. Epidemiologic studies in gastric cancer. In: Ho D (editor): Gastric cancer. New York: Churchill Livingstone; 1988. pp. 1-25.
3. Kohne CH, Wils JA, Wilke HJ. Developments in the treatment of gastric cancer in Europe. Oncology 2000; 14 (12 Suppl):22-25.
4. Wils J. Treatment of gastric cancer. Curr Opin Oncol 1998; 10:357-361.
5. Janunger KG, Hafstrom L, Nygren P. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001; 40:309-326.
6. Jennerwein MM, Eastman A, Khokhar A. Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexane platinum (II) complexes. Chem Biol Interact 1989; 70:39-49.
7. Dunn T, Schmoll HJ, Grunwald V, Bokemeyer C, Casper J. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 1997; 15:109-114.
8. Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 1995; 15:393-398.
9. Becouarn D, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients: Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998; 16:2739-2744.
10. Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Bendetti-Panici P, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000; 18:1193-1202.
11. Garufi C, Nistico C, Brienza S, Vaccaro A, D'Ottavio A, Zappala AR, et al. Single-agent oxaliplatin in pretreated advanced breast cancer patients:a phase II study. Ann Oncol 2001; 12:179-182.
12. Monnet I, Brienza S, Hugret F, Voisin S, Gastiaburu J, Saltiel JC, et al. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC): Association pour le Traitement des Tumeurs Intrathoraciques. Eur J Cancer 1998; 34:1124-1127.
13. Kim DY, Kim JH, Lee SH, Kim TY, Heo DS, Bang YJ, Kim NK. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 2003; 14:383-387.
14. Louvet C, André T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20:4543-4548.
15. Extra JM, Espie M, Calvo F, Ferne C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25:299-303.
16. de Gramont A, Figer A, Seymour M, Homerin C, Hmissi A, Cassidy J. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
17. Fischel JL, Etienne MC, Formento P, Milano G. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 1998; 4:2529-2535.
18. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22:658-663.
19. De Vita F, Orditura M, Matano E. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 92:1644-1649.
20. Chao Y, Yeh KH, Chang CJ, Chen LT, Chao YY, Wu MF, et al. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 2004; 91:453-458.
21. Ishiyama M, Shiga M, Sasamoto K, Mizogichi M, He P. A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull 1993; 41:1118.
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
23. Kern W, Braess J, Bottger B, Kaufmann CC, Hiddeman W, Schleyer E. Oxaliplatin pharmacokinetics during a four-hour infusion. Clin Cancer Res 1999; 5:761-765.
24. Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003; 21:2664-2672.
25. Scanlon KJ, Safirstein RL, Thies H, Gross RB, Waxman S, Guttenplan JB. Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells. Cancer Res 1983; 43:4211-4215.
26. Krebs HA, Hems R, Tyler B. The regulation of folate and methionine metabolism. Biochem J 1976; 158:341-353.
27. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83:8923-8925.
28. Gamelin E, Boisdron-Cell M, Allain P, Turcant A, Delva R, Cailleux A, et al. Pharmacokinetic interference between oxalipltin (LOHP) and fluorouracil: delayed 5-FU metabolism inhibition by LOHP. Proc Am Soc Clin Oncol 1997; 38:223.
29. Milano G, Etienne MC. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics 1994; 4:301-306.
30. Esaki T, Nakano S, Tatsumoto T, Kuroki-Migita M, Mitsugi K, Nakmura M, et al. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res 1992; 52:6501-6506.
31. Fujishima H, Nakano S, Esaki T, Tatsumoto T, Kondo T, Niho Y. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line. Oncol Res 1997; 9:167-172.
32. Yeh KH, Cheng AL,Wan JP, Lin CS, Liu CC. Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells. Anticancer Drugs 2004;15:371-376.
33. Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, Stoter G, et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 1998; 41:307-316.
34. 2 arrest and DNA double-strand breaks. Cancer Res 1988; 48:4484-4488.
35. Page JD, Husain I, Sancar A, Chaney SG. Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry 1990; 29:1016-1024.
36. Pratesi G, Gianni L, Manzotti C, Zunino F. Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice. Cancer Chemother Pharmacol 1988; 21:237-240.
37. Trave F, Rustum YM, Goranson J. Synergistic antitumor activity of cisplatin (DDP) and 5-fluorouracil (FUra) in mice bearing leukemia L1210 cells. Proc Am Assoc Cancer Res 1985; 26:1270.
38. Vietti T, Coulter D, Valeriote F. Interval and sequence dependent lethal effects of cis-diammine dichloroplatinum (Cis-Pt) in coordination with other agents. Proc Am Assoc Cancer Res 1979; 20:818.
39. Kuroki M, Nakano S, Mitusgi K, Ichinose I, Anzai K, Nakamura M, et al. In vivo comparative therapeutic study of optional administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell lines. Cancer Chemother Pharmacol 1992; 29:273-276.
40. Esaki T, Nakano S, Masumoto N, Fujishima H, Niho Y. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int J Cancer 1996; 65:479-484.
41. Fischel JL, Formento P, Ciccolini J, Rostagno P, Etienne MC, Catalin J, et al. Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br J Cancer 2002; 86:1162-1168.